The FDA has granted fast-track designation to Vaxxinity's experimental vaccine for Alzheimer's disease.
The immunotherapeutic vaccine candidate targets a toxic peptide called amyloid beta that is believed to damage the brain and trigger Alzheimer's.
The FDA's fast track program is designed to expedite the development and review of drugs intended to treat serious or life-threatening conditions.
Vaxxinity is slated to launch a phase 2B trial for the vaccine later this year, the company said in a May 2 press release.
Learn more here.